PTK2 and neoplasm: Based on these studies and on the deleterious role of FAK activity in both tumor and stromal (endothelial and fibroblastic) cells [310,313,316], pharmacologic FAK inhibitors are now tested in several clinical trials, in combination with chemotherapies and/or with immunotherapies (NCT02546531, NCT02758587, NCT03287271, NCT04109456).